Androgen receptor-mediated transcriptional repression targets cell plasticity in prostate cancer.

ABSTRACT: Androgen receptor (AR) signaling remains the key therapeutic target in the management of hormone-naïve-advanced prostate cancer (PCa) and castration-resistant PCa (CRPC). Recently, landmark molecular features have been reported for CRPC, including the expression of constitutively active AR variants that lack the ligand-binding domain. Besides their role in CRPC, AR variants lead to the expression of genes involved in tumor progression. However, little is known about the specificity of their mode of action compared with that of wild-type AR (AR-WT). We performed AR transcriptome analyses in an androgen-dependent PCa cell line as well as cross-analyses with publicly available RNA-seq datasets and established that transcriptional repression capacity that was marked for AR-WT was pathologicall

SUBMITTER: Erdmann E 

PROVIDER: S-EPMC9462842 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature